RxDoctor Payments Data

Ryan Dunn, MD

Pulmonary Disease · Sarasota, FLNPI 1114258167

Payments from drug & device makers

$39,245in general payments, 2019–2025

Across 64 payments — averaging $613.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$23K
  • United Therapeutics Corporation$9K
  • Intuitive Surgical$6K
  • GSK$334
  • AstraZeneca$324
  • Genentech USA, Inc.$101
  • plus $71 from 2 others

What the payments were for

  • Speaking & faculty fees$20,27567%
  • Travel & lodging$4,40115%
  • Food & beverage$1,3354%
  • Education$4,08614%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim25$23,319
United Therapeutics Corporation5$9,199
Intuitive Surgical8$5,897
GSK9$334
AstraZeneca11$324
Genentech USA, Inc.3$101
Insmed, Inc.2$51
Inogen, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,245 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$442,126
Medicare patients
1,024
Services billed
3,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter540$543,806
OfevNintedanib Esylate12$160,786
Breo ElliptaFluticasone/Vilanterol118$77,367
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr71$61,569
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$58,845
Spiriva RespimatTiotropium Bromide17$23,891
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$20,052
SymbicortBudesonide/Formoterol Fumarate24$10,923
Advair HfaFluticasone Propion/Salmeterol19$8,379
Albuterol Sulfate HfaAlbuterol Sulfate259$5,385
Mycophenolate Mofetil13$2,856
BreynaBudesonide/Formoterol Fumarate15$2,678
Azithromycin167$2,417
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$2,152
Wixela InhubFluticasone Propion/Salmeterol23$1,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$334$682,743729 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$23,319$204,72955 claims
AstraZenecaBreztri Aerosphere, Symbicort$324$69,76883 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →